Clinical Scorecard: A New Diagnostic Target in Insulinoma

At a Glance

Key Highlights

• DOCK10 is overexpressed in insulin-secreting tumor components compared to normal tissue.
• DOCK10 staining accurately identifies clinically active lesions over insulin staining.
• Single-cell RNA sequencing shows DOCK10 enrichment in insulin-secreting tumor cell populations.
• Reducing DOCK10 expression decreases glucose-stimulated insulin secretion.
• Pharmacologic inhibition of Cdc42 signaling pathway reduces insulin hypersecretion.

Guideline-Based Recommendations

Diagnosis

• Utilize DOCK10 immunostaining to differentiate between insulin-secreting and non-secreting tumors.

Management

• Consider targeting DOCK10 and associated pathways in therapeutic strategies for insulinoma.

Monitoring & Follow-up

• Monitor DOCK10 levels as a potential biomarker for insulin secretion activity.

Risks

• Limitations include small sample size and potential variability in single-cell data.

Patient & Prescribing Data

Patients diagnosed with insulinoma, especially those with complex presentations.

DOCK10 may serve as a reliable marker for identifying functional tumor subpopulations.

Clinical Best Practices

• Incorporate DOCK10 assessment in the diagnostic workup of insulinoma.
• Utilize organoid models for ongoing research into insulinoma therapies.

References

• Cellular and Molecular Gastroenterology and Hepatology Study